

CBD ビジネスの今後の展望について

平成 30 年 1 月 7 日

昭和大学薬学部 佐藤 均

CBD に関する世界保健機構（WHO）の報告書が昨年 11 月に出され、CBD の臨床効果および安全性についてお墨付きが与えられたことで、CBD ビジネスは一段高いレベルに達している。安全性に関しては、副作用がないこと、習慣性や精神作用がないことなどが明記され、効果に関しては、下表を掲載した。

Table 1. Overview of diseases for which CBD may have therapeutic benefits taken from Pisanti et al (2017) [69]

Disease	Effects
Alzheimer's disease	Antinflammatory, antioxidant, antiapoptotic in <i>in vitro</i> and <i>in vivo</i> models of A β -evoked neuroinflammatory and neurodegenerative responses.
Parkinson's disease	Attenuation of the dopaminergic impairment <i>in vivo</i> ; neuroprotection; improvement of psychiatric rating and reduction of agitation, nightmare and aggressive behaviour in patients.
Multiple sclerosis	Improved signs of EAE in mice, antinflammatory and immunomodulatory properties.
Huntington's disease	Neuroprotective and antioxidant in mice transgenic models; no significant clinically important differences in patients.
Hypoxia-ischemia injury	Short term neuroprotective effects; inhibition of excitotoxicity, oxidative stress and inflammation <i>in vitro</i> and in rodent models.
Pain	Analgesic effect in patients with neuropathic pain resistant to other treatments.
Psychosis	Attenuation of the behavioural and glial changes in animal models of schizophrenia; anti-psychotic properties on ketamine-induced symptoms
Anxiety	Reduction of muscular tension, restlessness, fatigue, problems in concentration, improvement of social interactions in rodent models of anxiety and stress; reduced social anxiety in patients.
Depression	Anti-depressant effect in genetic rodent model of depression.
Cancer	Antiproliferative and anti-invasive actions in a large range of cancer types; induction of autophagy-mediated cancer cell death; chemopreventive effects.
Nausea	Suppression of nausea and conditioned gaping in rats
Inflammatory diseases	Antinflammatory properties in several <i>in vitro</i> and <i>in vivo</i> models; inhibition of inflammatory cytokines and pathways.
Rheumatoid arthritis	Inhibition of TNF- α in an animal model
Infection	Activity against methicillin-resistant <i>Staphylococcus aureus</i>
Inflammatory bowel and Crohn's diseases	Inhibition of macrophage recruitment and TNF- α secretion <i>in vivo</i> and <i>ex vivo</i> ; reduction in disease activity index in Crohn's patients.
Cardiovascular diseases	Reduced infarct size through anti-oxidant and anti-inflammatory properties <i>in vitro</i> and <i>in vivo</i> .
Diabetic complications	Attenuation of fibrosis and myocardial dysfunction

これまで、米国における CBD のみの市場は年間売り上げ約 3000 億円と言われていたが、大麻（THC を含む）の使用に関してトランプ政権下ではこれまでよりも厳しく連邦法を適用することとなり、逆に CBD 関連商品のビジネスチャンスがさらに拡大すると考えられる。日本においても、2～3 年の時間差はあるものの、米国に追随することは確実と考えられる。